1. Introduction {#s1}
===============

As the opioid crisis continues in North America, clinicians and researchers need to understand factors that perpetuate opioid use and barriers to detoxification.^[@R2],[@R4],[@R19],[@R32],[@R33]^ There is a growing body of evidence that opioids can provide a pronociceptive force both centrally and peripherally, resulting in opioid-induced hyperalgesia (OIH).^[@R13],[@R20],[@R21],[@R28]^ When regular opioid use is stopped, some people experience a temporary return of pain at old healed injury sites, a phenomenon that we have documented and termed withdrawal-associated injury site pain (WISP).^[@R27]^ The current case study is the first to detail one individual\'s pain experience with opioid use and withdrawal to shed light on the possible relationship between OIH and WISP, as well as to provide a case example to assist in the identification of this phenomenon.

2. Methods {#s2}
==========

This case study was extracted from our mixed methods study that characterized WISP.^[@R27]^ The participant was recruited in 2014 from a primary care clinic providing methadone treatment in Vancouver, Canada. She provided written informed consent. She screened positive for WISP as per the published protocol and completed the 35-question survey as well as elaborated on her own experience in an in-depth interview, which was recorded and transcribed. The initial study protocol was approved by the Behavioral Research Ethics Board at the University of British Columbia and the Vancouver Coastal Health Research Ethics Board. In June of 2017, the participant was contacted again. She endorsed a draft of this case report provided to her, and through email and text provided a brief update of her pain and treatment experience in the intervening 3 years.

3. Results {#s3}
==========

A 34-year-old white woman (pseudonym "Alice") reported experiencing several twisting injuries of her right knee playing sports between the ages of 12 and 15. The original injury site pain (recalled as 4/10 on a 0--10 scale) associated with these injuries resolved in 2 to 3 days each time. She reported no knee pain, although an occasional click, for the subsequent 15 years and was medication free. At age 30, Alice began insufflating illicit oxycodone recreationally (not for pain) and developed an opioid use disorder (OUD).

In 2012, at age 32, she abruptly stopped the use of oxycodone 150 mg/d, morphine equivalent daily dose (MEDD) 225 mg (1:1.5 oral dose conversion chosen because of conflicting information regarding intranasal bioavailability).^[@R18],[@R22],[@R30]^ Alice reported experiencing moderate generalized withdrawal symptoms along with severe right knee pain (ie, WISP intensity 8/10 for 30 days, then 4/10 for 15 days). Subsequently, she reported being pain free for 7 months while opioid abstinent. Alice then reinitiated oxycodone insufflation and found that her right knee pain returned. She perceived escalation of injury site pain as her dose of opioids increased and attributed the etiology of the pain to a presumed chronic knee problem but wondered whether oxycodone was playing a role. Notably, each subsequent attempt at opioid cessation produced even greater right knee WISP (intensity 10/10) and generalized skin sensitivity, towards which she developed fear and aversion. By contrast, opioid withdrawal pain in the contralateral knee was mild (intensity 2/10) and not always present when opioids were stopped.

Alice cited WISP as a barrier to detoxification and opioid cessation. Despite many attempts at opioid cessation in the previous 2 years, she was able to go beyond the full 6 weeks of WISP symptoms only 3 times. On each of these 3 occasions, her right knee pain resolved completely. General withdrawal symptoms were a contributor to reinitiation of opioid use but were typically less intense (4/10) and somewhat shorter than WISP (30 days).

Alice reported that naproxen, ibuprofen, gabapentin, acetaminophen, and phenobarbital all diminished WISP somewhat during acute detoxification. She eventually tried detoxification with prescribed methadone (ie, 30-mg initial dose, then tapered by 5 mg/d), which eased WISP compared with withdrawal with no medication. At the time of the initial interview in 2014 at age 34, she was embarking on methadone maintenance treatment and had recently achieved a dose of 85 mg/d. Yet, she continued to use oxycodone for knee pain approximately 20 to 40 mg/d, ostensibly until her methadone dose could be further increased. At that point, the MEDD was 436 mg (1:4.6 conversion methadone to morphine and 1:1.5 oxycodone to morphine).^[@R22]^

Alice\'s key individual quotes related to her clinical presentation are found in Table [1](#T1){ref-type="table"}.

###### 

Quotes from Alice\'s narrative.

![](painreports-3-e648-g001)

In follow-up at age 37, Alice related that her methadone had gone as high as 200 mg per day in the past year (MEDD 920 mg).^[@R22]^ Although methadone had helped her not use illicit opioids, it had been overly sedating and never managed her knee pain well. So, in the previous months, she had tapered down on methadone to 30 mg/d (MEDD 138 mg) and then switched over to sublingual buprenorphine/naloxone (although did not state her dose). Alice reported feeling very well on this medication; she had no drug cravings, was clear minded, and had no knee pain. Alice had never heard of nor been offered naltrexone.

Alice recognized that knowledge of WISP might have helped her. She said "*I think it would have made it a lot easier...* \[*knowing*\] *that it\'ll actually go away.*"

4. Discussion {#s4}
=============

This case study illustrates that both opioid use and withdrawal can activate old healed injury site pain, which can increase with dose escalation and repeated withdrawal events. The timing and trajectory of WISP in this case is consistent with those of the development and resolution of OIH, which has also been shown to be both opioid dose dependent and withdrawal episode dependent.^[@R6],[@R12],[@R14],[@R15]^ Also, the pronociceptive changes that occur in OIH combined with catecholamine release and other factors has been linked with withdrawal-induced hyperalgesia, which in turn has been shown to last weeks to months in those with OUDs or on long-term opioid therapy for chronic noncancer pain.^[@R5],[@R26],[@R31],[@R34]^ For Alice, she displayed generalized skin sensitivity, indicating she may have developed OIH revealed during withdrawal because allodynia can comanifest with hyperalgesia. It is possible that this pain-sensitive state then uncovered peripheral or central sensitization that resulted from the original injury but was quiescent under normal circumstances.^[@R27],[@R35]^ Given that Alice experienced occasional clicking in her knee, it is possible that she had underlying pathology that was pain free under normal circumstances.

Perceived intensity and emotional fear of WISP acted as a barrier to opioid detoxification for Alice. This is in keeping with other studies showing that anxiety and fear can influence inflammation and pain perception.^[@R23],[@R29]^

Alice initially presumed that she had a chronic pain condition, when instead she had WISP and opioid lowering, detoxification or rotation was needed for the pain to resolve, as can be the case in OIH.^[@R1],[@R3],[@R20]^ Nonsteroidal anti-inflammatories and gabapentin were among the medications that subjectively helped relieve her symptoms of WISP consistent with medications found to relieve WISP and OIH in other studies.^[@R1],[@R3],[@R8],[@R27]^ Pain during and immediately after opioid detoxification has been shown by other authors to be a risk factor for reinitiation of opioid use.^[@R24]^

At the time of the first interview, Alice had decided to initiate methadone treatment, which has been shown to be equally efficacious to buprenorphine/naltrexone in the treatment of OUD in noninjection opioid analgesia users.^[@R25]^ Despite methadone being a racemic mixture in which one enantiomer is a mu opioid receptor agonist and one an NMDAr antagonist, OIH can still develop.^[@R7]^ Interestingly, a high proportion of people with OUDs report having what they presume is chronic pain, even after conversion to methadone.^[@R7],[@R10],[@R11]^ Ultimately for Alice, the methadone could not control her right knee pain, although helped her OUD. In her view, Alice benefitted from once daily oral buprenorphine/naloxone therapy. Both her pain and her addiction were managed. This is consistent with another study showing a fifty percent drop in pain when converted from high-dose pharmaceutical grade opioids to buprenorphine, but is in contrast to a report of patients with previous heroin use still displaying OIH on buprenorphine.^[@R7],[@R9]^ One is patient self-report, and the other an experimentally elicited response, which may account for the difference.

Alice had never been offered naltrexone, which is a reminder for clinicians to discuss all medication options with patients. Naltrexone is an antagonist at both mu opioid receptor and toll-like receptor 4 on microglial cells, which shows mixed results in preclinical trials to treat OIH, as well as being a treatment for OUD.^[@R1],[@R16],[@R17]^

Limitations of this study include Alice\'s omission of her buprenorphine/naloxone dose for comparison. Also, it is unknown if Alice may build symptoms of OIH and WISP overtime on buprenorphine/naloxone.

5. Conclusion {#s5}
=============

We present the first detailed description of a case in which both opioid use and withdrawal could reactivate injury site pain. This woman\'s experience illustrates that the timing, trajectory, and neuropathic features of WISP reported here are consistent with those previously reported for the development and resolution of OIH, possibly linking these phenomena.
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